About us

Boost Beyond Boundaries

History

Astrogen History

With years of clinical experience, Astrogen is exploring new horizons
in medications development field at an unprecedented speed.

  • June Selected for the "Unicorn Bridge" Project (Ministry of SMEs and Startups)
  • Participated in BIO USA 2026
  • February Received the "Folia Award" for the AST-001 Phase 2 Clinical Trial Paper (PCN)
  • January Signed a License-Out Agreement for AST-001
  • across 16 Middle Eastern Countries (USD 200M + Royalties)
2026
2026
2025
2025
  • September Selected as a "Preliminary Unicorn Company"
  • Selected for the SME Technology Innovation Development Project
  • June Submitted the NDA for AST-001 (Speregen) to the MFDS
  • December Completed the Last Subject Observation for the AST-001 Phase 3 Clinical Trial
  • Publication of the AST-001 PK/PD Modeling Study in Frontiers in Pharmacology (SCI Journal)
  • November Designated as an Excellent Corporate Research Institute for the Second Half of 2024
  • October Publication of AST-001 Phase 2 Clinical Trial Results in PCN (SCI Journal)
  • June Participated in BIO USA 2024
  • Received Orphan Drug Designation (ODD) from MFDS
  • April Selected for the "Super Gap Startup 1000+" Project (Ministry of SMEs and Startups)
  • January Secured KRW 12.5 Billion in Series C Investment
2024
2024
2023
2023
  • October Oral Presentation of AST-001 Phase 2 Results at the 70th AACAP Annual Meeting
  • Certified as an INNO-BIZ Company
  • September Completion of the Clinical Study Report for the AST-001 Continuous Treatment Follow-up Study (CSR)
  • August First Subject Enrolled in the AST-001 Phase 3 Clinical Trial
  • ISO 9001 certification
  • ISO 14001 certification
  • ISO 45001 certification
  • July Selected as a "Baby Unicorn Plus Company" (Ministry of SMEs and Startups)
  • May Last Subject Observation Completed for the AST-001 Continuous Treatment Follow-up Study
  • August Selected as an Employment-Friendly Company (Daegu Metropolitan City)
  • Selected for the BIG3 Project (Ministry of SMEs and Startups)
  • Selected for the Startup Growth Technology Development Project
  • Secured KRW 3 Billion in Bridge 2 Investment
  • June Publication of the AST-001 PK Modeling Study in Frontiers in Pharmacology (SCI Journal)
  • May Completed the Final Subject Observation for the AST-001 Phase 2 Clinical Trial
  • February Secured KRW 9 Billion in Bridge 1 Investment
  • January First Subject Enrolled in the AST-001 Continuous Treatment Follow-up Study
2022
2022
2021
2021
  • December Received the Presidential Citation for Venture Startup Promotion
  • Certified as a "Family-Friendly Company" (Ministry of Gender Equality and Family)
  • November Designated as an Excellent Corporate R&D Center (Ministry of Science and ICT)
  • October Introduced Astrogen's ESG Ethical Management
  • September Published Astrogen's ESG Report on the Website
  • Selected as a "Pre-Star Company" (Daegu Metropolitan Government)
  • February Completion of the AST-001 Phase 1 Clinical Study Report (CSR)
  • Enrolled the First Subject in the AST-001 Phase 2 Clinical Trial
  • December Secured KRW 13 Billion in Series B Investment
  • Received the Grand Prize at the Daegu Startup Awards (Daegu Center for Creative Economy Innovation)
  • Received the Minister's Award from the Ministry of Trade, Industry and Energy for Revitalization of the Free Economic Zone
  • November Selected as a "National Representative Innovative Company" (Financial Services Commission)
  • August Opened Astrogen's Pharmaceutical Research Institute Office in Naju
  • July Received IND Approval for the AST-001 Phase 2 Clinical Trial
  • June Selected as a "Baby Unicorn Plus Company" (Ministry of SMEs and Startups)
  • May Completed Construction of Astrogen's New Office Building
  • March Received IND Approval for the AST-001 Phase 1 Clinical Trial
2020
2020
2019
2019
  • December Began Construction of Astrogen's New Building and Research Center
  • November Selected as a Frontier Venture Company (KIBO)
  • Selected as an "A+ Member" (KIBO)
  • August Secured KRW 5 Billion in Series A Investment
  • May Obtained Approval to Move into the Daegu-Gyeongbuk Medical Cluster
  • March Opened Astrogen's Business Development Division Office in Seoul
  • August Secured KRW 1.9 Billion in Pre-Series A Seed Investment
  • January Obtained Approval for the Astrogen Research Center
2018
2018
2017
2017
  • July Founded Astrogen, inc.
  • Obtained Venture Company Certification